AstraZeneca has entered into a partnership with insitro to identify treatments for challenging liver and heart diseases. This collaboration, which involves a $40 million upfront payment, could reach $1.46 billion in total milestones. The companies aim to tackle metabolic dysfunction-associated steatohepatitis and cardiomyopathies through insitro’s AI platform.
aiweekly.co.in
“Where Machines Make Headlines.”